Thermo Fisher Scientific Inc. $TMO Stake Boosted by Park National Corp OH

Park National Corp OH increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1,067.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,329 shares of the medical research company’s stock after buying an additional 5,787 shares during the quarter. Park National Corp OH’s holdings in Thermo Fisher Scientific were worth $4,272,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Baker Tilly Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 4.7% in the third quarter. Baker Tilly Wealth Management LLC now owns 1,525 shares of the medical research company’s stock valued at $1,030,000 after acquiring an additional 69 shares during the last quarter. Ferguson Wellman Capital Management Inc. increased its position in Thermo Fisher Scientific by 11.9% in the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 86,904 shares of the medical research company’s stock worth $58,665,000 after buying an additional 9,275 shares during the period. Violich Capital Management Inc. grew its position in Thermo Fisher Scientific by 21.4% in the 3rd quarter. Violich Capital Management Inc. now owns 1,335 shares of the medical research company’s stock worth $901,000 after purchasing an additional 235 shares during the last quarter. Polaris Financial Partners acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at approximately $32,000. Finally, Global Wealth Strategies & Associates bought a new position in Thermo Fisher Scientific in the third quarter worth $271,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. CLSA began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price objective on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “overweight” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $628.78.

Thermo Fisher Scientific Stock Up 2.1%

TMO stock traded up $13.63 during mid-day trading on Monday, reaching $668.43. The company had a trading volume of 653,629 shares, compared to its average volume of 2,243,602. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $683.63. The company has a market capitalization of $247.15 billion, a price-to-earnings ratio of 35.93, a PEG ratio of 2.74 and a beta of 0.87. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a 50 day simple moving average of $618.62 and a two-hundred day simple moving average of $535.16.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.